Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers

Lynch Syndrome I (Site-specific Colonic Cancer) Clinical Trial

— CaPP3 Israel  

Official title:

A Randomised Double Blind Dose Non-inferiority Trial of a Daily Dose of 600mg Versus 300mg Versus 100mg of Enteric Coated Aspirin as a Cancer Preventive in Carriers of a Germline Pathological Mismatch Repair Gene Defect, Lynch Syndrome

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02497820
• Other study ID #: 0246-14-TLV
• Status: Not yet recruiting
• Phase: Phase 3
• First received: July 7, 2015
• Last updated: August 24, 2016
• Start date: September 2016
• Est. completion date: September 2027

Study information

• Verified date: August 2016
• Source: Tel-Aviv Sourasky Medical Center
• Contact: Maayan Jean, .M.Sc
• Phone: 0524496437
• Email: md0905[@]gmail.com
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological mismatch repair gene defect, Lynch Syndrome. Project 3 in the Cancer Prevention Programme (CaPP3).

Description:

Study design: A randomised, double-blind, dose non-inferiority study.

Study Intervention: Enteric-coated aspirin 100mg, 300mg or 600mg blinded dose daily followed by daily 100mg open label dose daily.

Primary objective: To determine whether the cancer preventive properties of enteric coated aspirin in Lynch syndrome are dose sensitive by comparing overall cumulative Lynch syndrome cancer incidence rates after 5 years in people who took 100mg, 300mg or 600mg enteric coated aspirin for at least 2 years.

Secondary objectives: Compare overall cumulative incidence of primary colorectal cancers using Poisson regression to allow for multiple primaries in individual patients in the three treatment groups.

Compare overall cumulative incidence of primary endometrial cancers using Poisson regression to allow for multiple primaries in individual patients in the three treatment groups.

Compare overall cumulative incidence of cancers of all types, using Poisson regression to allow for multiple primaries in individual patients in the three treatment groups.

The burden of adverse events associated with the different aspirin doses in this relatively young and healthy population will be documented.

Primary outcome: The number of new primary mismatch repair deficient cancers ("Lynch syndrome cancers") at 5 years and beyond which develop in participants who remain on prescribed treatment for a minimum of 2 years.

Number of study sites: 4 ISRAEL sites. 20 sites all over the world.

Study population/size: 300 patients in ISRAEL. UK 1000-1500 patients. Total with International 3,000 patients.

Study duration: 7 years.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1800
• Est. completion date: September 2027
• Est. primary completion date: September 2027
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female patients = 18 years.

2. Confirmed germline pathological variant in one of the mismatch repair genes; MSH2, MLH1, PMS2 or MSH6 or a 3' EPCAM deletion associated with MSH2 silencing or be a carriers of a constitutional epimutation manifesting a classic Lynch syndrome phenotype.

3. Able to swallow tablets.

4. Provision of voluntary written informed consent.

Exclusion Criteria:

1. Regular use of a non-steroidal anti-inflammatory agent (except aspirin*) on a prescription and/or long-term basis. Regular is defined as > 3 doses per week.

2. Regular use of aspirin (> 3 doses per week or on a prescription basis) that cannot be replaced with any one of the randomised arms of the study followed by 100mg dose.

3. Current methotrexate use at a weekly dose of = 15mg.

4. Known aspirin intolerance or hypersensitivity, including aspirin-sensitive asthma.

5. Existing clinically significant liver impairment.

6. Existing renal failure.

7. Confirmed active peptic ulcer disease within the previous three months.

8. Known bleeding diathesis or concomitant warfarin therapy.

9. Inability to comply with study procedures and agents.

10. Women reporting that they are pregnant or actively planning to achieve a pregnancy within the next two years.

11. Women who are breastfeeding.

12. Any significant medical illness that would interfere with study participation.

• Previous use of aspirin for medicinal purposes does not exclude enrolment but duration and quantity need to be documented in detail

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Colonic Neoplasms
• Colorectal Neoplasms, Hereditary Nonpolyposis
• Lynch Syndrome I (Site-specific Colonic Cancer)
• Syndrome

Intervention

Drug:
• Aspirin
Aspirin (acetylsalicylic acid) has a marketing approval for use in the EU and is widely available as an over the counter medicine. However it is not being used within its licensed indication and the aspirin (at any dose in this study) will be treated as an investigational medicinal product (IMP). Tablets will be provided as enteric-coated 100mg or 300mg tablets for oral use. All patients will receive at least some dose of aspirin but blinding to the actual dose will be achieved by the use of 'dummy' tablets using the same excipients as in the active formulation of the aspirin minus the active ingredient. The aspirin and dummy tablets should be stored at room temperature below 25°C in a dry place.

Locations

Country	Name	City	State
Israel	Sourasky Medical Center	Tel Aviv

Sponsors (5)

Lead Sponsor	Collaborator
Tel-Aviv Sourasky Medical Center	Rabin Medical Center, Rambam Health Care Campus, Sheba Academic Medical Center Hospital, Soroka Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	cancer preventive properties of enteric coated aspirin in Lynch syndrome are dose sensitive by comparing overall cumulative Lynch syndrome cancer	The number of new primary mismatch repair deficient cancers ("Lynch syndrome cancers") at 5 years which develop in participants who remain on prescribed treatment for a minimum of 2 years.	5 years	No
Secondary	Overall cumulative of new colorectal cancers incidence rates after 5 years	The number of new colorectal cancers at 5 years which develop in participants who remain on prescribed treatment for a minimum of 2 years.	5 years	No
Secondary	Overall cumulative of new endometrial cancers incidence rates after 5 years	The number of new endometrial cancers at 5 years which develop in participants who remain on prescribed treatment for a minimum of 2 years.	5 years	No
Secondary	Overall cumulative of new new cancers of all types incidence rates after 5 years	• The number of new cancers of all types at 5 years which develop in participants who remain on prescribed treatment for a minimum of 2 years.	5 years	No
Secondary	Overall cumulative of changes in the titre of frameshift peptide antibodies after 2 & 5 years	Changes at 2 & 5 years in the titre of frameshift peptide antibodies from commencement of the prescribed treatment.	5 years	No
Secondary	Overall cumulative of of new adenomas at five years	The number of new adenomas at five years	5 years	No